Drug intelligence / Profile preview

MNI-558

Development stage: Unknown
Lead developer: Invicro
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MNI-558 (specifically [18F]MNI-558) is an experimental radiopharmaceutical used in PET imaging for Alzheimer's disease research. It is a radioactive drug designed to bind to beta-amyloid deposits in the brain, allowing for their visualization during PET scans. It was used in a Phase 0 clinical trial to evaluate its efficacy and safety for detecting cerebral amyloid beta in patients with Alzheimer's disease compared to healthy volunteers. The drug was not FDA-approved at the time of the clinical trial.

Other names: [18F]MNI-558

Targets

Amyloid fibrils

Beyond the preview

Go deeper on MNI-558.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MNI-558.

Explore the full profile